search results for

refine results

sort by


result type


Press Releases

Eli Lilly CEO: Looking for 'market based solutions' on drug costs

Medicare Part D is really the model going forward, says David Ricks, Eli Lilly CEO, talking about his meeting with President Trump and the pharma industry's move to provide competitive pricing on prescriptions. Also Ricks shares his thoughts on tax reform and the impact of regulations.


Cramer Remix: What is really freaking investors out about Trump

Jim Cramer identified a concerns lurking beneath the surface among shareholders and executives in the business community.


Cramer warns pharma still not safe to own despite Trump’s softened stance

Jim Cramer expected Donald Trump to walk into his meeting with pharma executives with a baseball bat. Instead, he jawboned them.


Making pharma great again?

CNBC's Meg Tirrell reports on President Trump's meeting with big pharmaceutical CEOs, and how it is impacting the biotech sector. The "Fast Money" traders weigh in.


Fmr. Onyx CEO: Responsibility to find and research cures doesn't come cheap

Tony Coles, Yumanity Therapeutics CEO, former Onyx CEO, weighs in on President Trump's drug pricing rhetoric and meeting with pharma leaders. With CNBC's Meg Tirrell.


Klain: Pharma will be net winner in exchange with Trump administration

Ronald Klain, former White House senior advisor, and Vamil Divan, Credit Suisse pharma analyst, weigh in on President Trump's plans to bring down drug prices and the potential impact on the pharmaceutical industry. With CNBC's Meg Tirrell.